To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
New Swiss biotech fund aims for E150m
Three partners, including the former manager of BB Biotech and the former head of Aventis' R&D in Europe and Japan, have set up Brilleon Capital.
